Trade

with

SciClone Pharmaceuticals
(NASDAQ: SCLN)
AdChoices
7.58
-0.30
-3.81%
After Hours :
7.58
0.00
0.00%

Open

7.91

Previous Close

7.88

Volume (Avg)

486.28k (510.11k)

Day's Range

7.57-8.00

52Wk Range

4.24-8.00

Market Cap.

402.51M

Dividend Rate ( Yield )

-

Beta

2.13

Shares Outstanding

51.08M

P/E Ratio (EPS)

18.80 (0.42)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 127.06M

    • Net Income

    • 10.96M

    • Market Cap.

    • 402.51M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 17.73

    • PEG (Price/Earnings Growth) Ratio

    • 1.41

    • Beta

    • 2.13

    • Forward P/E

    • 20.79

    • Price/Sales

    • 3.33

    • Price/Book Value

    • 2.61

    • Price/Cash flow

    • 15.24

      • EBITDA

      • 14.17M

      • Return on Capital %

      • 12.85

      • Return on Equity %

      • 15.01

      • Return on Assets %

      • 12.85

      • Book Value/Share

      • 3.02

      • Shares Outstanding

      • 51.08M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 8.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 11.00

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • 14.00

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • 18.62

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 84.72

            • 64.72

            • Pre-Tax Margin

            • 18.83

            • 13.77

            • Net Profit Margin

            • 17.73

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • 85.10

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 16.20

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • 15.50

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.33

              • Current Ratio

              • 6.06

              • 1.52

              • Quick Ratio

              • 5.27

              • 0.87

              • Interest Coverage

              • 347.62

              • 6.77

              • Leverage Ratio

              • 1.15

              • 1.91

              • Book Value/Share

              • 3.02

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 18.80

                • 63.69

                • P/E Ratio 5-Year High

                • 18.86

                • 237.47

                • P/E Ratio 5-Year Low

                • 4.96

                • 19.71

                • Price/Sales Ratio

                • 3.33

                • 3.57

                • Price/Book Value

                • 2.61

                • 3.35

                • Price/Cash Flow Ratio

                • 15.24

                • 21.41

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 15.01

                    (18.60)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • 12.85

                    (15.20)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • 14.95

                    (18.00)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • 39.51k

                  • 27.79k

                  • Inventory Turnover

                  • 1.58

                  • 1.80

                  • Asset Turnover

                  • 0.72

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  10.43M
                  Operating Margin
                  8.21
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  15.24
                  Ownership

                  Institutional Ownership

                  62.76%

                  Top 10 Institutions

                  44.70%

                  Mutual Fund Ownership

                  27.79%

                  Float

                  88.43%

                  5% / Insider Ownership

                  5.00%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Franklin Biotechnology Discovery

                  •  

                    2,320,100

                  • 19.45

                  • 4.47

                  • Franklin Biotechnology Discovery Fund

                  •  

                    1,602,260

                  • 1.64

                  • 3.14

                  • SEB Concept BioTech

                  •  

                    804,800

                  • 17.54

                  • 1.58

                  • iShares Russell 2000 (AU)

                  •  

                    792,022

                  • -0.90

                  • 1.77

                  • Vanguard Total Stock Mkt Idx

                  •  

                    694,155

                  • 0.00

                  • 1.36

                  • iShares Nasdaq Biotechnology

                  •  

                    665,518

                  • -1.85

                  • 1.49

                  • QS Batterymarch US Sm Cp Eq Ptf

                  •  

                    495,887

                  • 0.00

                  • 0.97

                  • DFA U.S. Micro Cap Portfolio

                  •  

                    471,651

                  • 0.00

                  • 0.92

                  • Vanguard Extended Market Index Fund

                  •  

                    447,519

                  • 0.25

                  • 0.88

                  • DFA U.S. Small Cap Portfolio

                  •  

                    336,451

                  • 0.00

                  • 0.66

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Franklin Advisers, Inc.

                  •  

                    4,685,542

                  • +27.80%

                  • 9.15

                  • GL Partners Capital Management Ltd

                  •  

                    3,758,217

                  • +13.54%

                  • 7.07

                  • LSV Asset Management

                  •  

                    2,495,487

                  • -2.31%

                  • 4.87

                  • BlackRock Fund Advisors

                  •  

                    2,298,030

                  • -11.84%

                  • 4.49

                  • Dimensional Fund Advisors, Inc.

                  •  

                    2,297,884

                  • +5.97%

                  • 4.49

                  • Nantahala Capital Management, LLC

                  •  

                    1,839,628

                  • +4.40%

                  • 3.59

                  • Vanguard Group, Inc.

                  •  

                    1,457,968

                  • +0.01%

                  • 2.85

                  • Acadian Asset Management LLC

                  •  

                    1,231,135

                  • +23.72%

                  • 2.40

                  • State Street Corp

                  •  

                    975,775

                  • -1.79%

                  • 1.91

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  Slow Growth

                  Style

                  Small Value

                  SciClone Pharmaceuticals, Inc., a Delaware corporation was incorporated in 1990. The Company is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, inf...moreectious diseases and cardiovascular disorders. The Company’s primary product, ZADAXIN (thymalfasin) is approved in over 30 countries and may be used for the treatment of HBV, HCV, and certain cancers, and as a vaccine adjuvant according to the local regulatory approvals. It markets approximately 10 partnered products in China, including Aggrastat, an interventional cardiology product. The Company operates is two segments based on the nature and locations of its customers: China and the rest of the world which includes its US and Hong Kong operations. It competitors for e...morexisting and future products include pharmaceutical companies, biotechnology firms, universities and other research institutions, in the US, China and other territories, that are actively engaged in research and development or marketing of products in the therapeutic areas the Company is pursuing. The Company’s products in clinical development in the US, China and other foreign countries are subject to approval by the FDA, the SFDA and similar regulatory authorities.lessless

                  Key People

                  Dr. Friedhelm Blobel,PhD

                  CEO/Director/President

                  Mr. Hong Zhao

                  CEO, Divisional/CEO, Subsidiary

                  Mr. Jon S. Saxe

                  Chairman of the Board/Director

                  Wilson W. Cheung

                  CFO/Chief Accounting Officer/Secretary/Senior VP, Divisional

                  Lan Xie

                  CFO, Divisional/Vice President, Divisional

                  • SciClone Pharmaceuticals

                  • 950 Tower Lane

                  • Foster City, CA 94404

                  • USA.Map

                  • Phone: +1 650 358-3456

                  • Fax: +1 650 358-3469

                  • sciclone.com

                  Incorporated

                  1990

                  Employees

                  570

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: